IGC Pharma Financials - Benzinga

SPY767.86 QQQ737.22−0.98%BTC/USD82,744.85−2.01%DIA515.67−0.35%GLD380.10−3.38%TLT78.85−0.59%

IGC Pharma Inc

IGCAMEX

Trade with Public

Trade with Public

$0.2824

0.00130.46%

At close: Sep 25, 5:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

IGC Pharma Financials

IGC Pharma (IGC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate

IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same

Benzinga Newsdesk

PRO
IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate

IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period

Benzinga Newsdesk

PRO
IGC Pharma Q2 EPS $(0.02), Inline, Sales $191.000K Miss $325.000K Estimate

IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $191.000 thousand

Benzinga Newsdesk

PRO
IGC Pharma Q1 EPS $(0.02) Beats $(0.03) Estimate, Sales $328.000K Beat $326.000K Estimate

IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 20 percent. This is a 33.33 percent increase over losses of $(0.03) per share from the same

Benzinga Newsdesk

PRO
IGC Pharma Q4 EPS $(0.01) Beats $(0.02) Estimate, Sales $330.000K Beat $305.000K Estimate

IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 75 percent increase over losses of $(0.04) per share from the same period

Benzinga Newsdesk

Insights Ahead: IGC Pharma's Quarterly Earnings

Benzinga Insights